# Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream

> **NCT05220293** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oticara Australia PTY LTD** · enrollment: 2 (actual)

## Conditions studied

- Chronic Rhinosinusitis (Diagnosis)

## Interventions

- **DRUG:** Betamethasone Dipropionate Nasal Cream 0.0644%
- **DEVICE:** Pre-filled syringe and applicator device

## Key facts

- **NCT ID:** NCT05220293
- **Lead sponsor:** Oticara Australia PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-23
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Single site study OT-007 re-opened as multi-site OT-007B study
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05220293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05220293, "Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05220293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*